These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1221 related articles for article (PubMed ID: 33190147)

  • 1. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
    JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.
    Nissen SE; Lincoff AM; Wolski K; Ballantyne CM; Kastelein JJP; Ridker PM; Ray KK; McGuire DK; Mozaffarian D; Koenig W; Davidson MH; Garcia M; Katona BG; Himmelmann A; Loss LE; Poole M; Menon V; Nicholls SJ
    JAMA Cardiol; 2021 Aug; 6(8):910-917. PubMed ID: 33993205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
    Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
    Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
    JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History and future of omega-3 fatty acids in cardiovascular disease.
    Sperling LS; Nelson JR
    Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G; Mushtaq S
    Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
    Alfaddagh A; Elajami TK; Ashfaque H; Saleh M; Bistrian BR; Welty FK
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review.
    Balk EM; Adams GP; Langberg V; Halladay C; Chung M; Lin L; Robertson S; Yip A; Steele D; Smith BT; Lau J; Lichtenstein AH; Trikalinos TA
    Evid Rep Technol Assess (Full Rep); 2016 Aug; (223):1-1252. PubMed ID: 30307737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study.
    Allaire J; Vors C; Harris WS; Jackson KH; Tchernof A; Couture P; Lamarche B
    Br J Nutr; 2019 Jun; 121(11):1223-1234. PubMed ID: 30854986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.